Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy

被引:2
|
作者
Hu, Zhongjie [1 ]
Liu, Ying [2 ]
Qiu, Lixia [1 ]
Fan, Zuopeng [1 ]
Nie, Wei [1 ]
Liang, Shan [1 ]
Jin, Ronghua [3 ]
机构
[1] Capital Med Univ, Beijing Youan Hosp, Dept Hepatitis & Tox Liver Dis C, Beijing 100069, Peoples R China
[2] Capital Med Univ, Beijing Youan Hosp, Management Ctr Med Record, Beijing 100069, Peoples R China
[3] Capital Med Univ, Beijing Youan Hosp, Beijing 100069, Peoples R China
关键词
Hepatitis C virus; Genotype; 1b; Amino acid 70 substitution; Interferon; Viral kinetics; HEPATITIS-C VIRUS; AMINO-ACID SUBSTITUTIONS; VIROLOGICAL RESPONSE; JAPANESE PATIENTS; COMBINATION THERAPY; INHIBITS INTERFERON; PREDICTIVE FACTORS; GENETIC-VARIATION; NON-A; PROTEIN;
D O I
10.1186/s12985-015-0451-9
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-alpha plus ribavirin combination therapy (PEG-IFN alpha/RBV). But the exact mechanisms remain unclear. The aim of this study was to investigate the dynamic response of wild and mutant core codon 70 strains to PEG-IFN alpha/RBV treatment. Methods: One hundred twelve Chinese patients with chronic HCV 1b infection were enrolled and received a standard protocol of 48 weeks of PEG-IFN alpha/RBV therapy and 24 consecutive weeks of follow-up. Serial blood samples were obtained at pretreatment baseline, and again at weeks 2, 4, 8, 12, and 24 during therapy for the quantification of 70R and 70Q/H strains. Dynamic characteristics and association with early virological response (EVR), sustained virological response (SVR) and IL28B genotypes were analyzed. Results: Of the 112 patients enrolled in this study, 93.8 % (105/112) were infected with mixture of 70R and 70Q/H strains before treatment. The 70Q/H strain was dominant in 20.5 % of patients. 42.9 % of patients with dominant 70Q/H exhibited EVR versus 88.6 % of patients with dominant 70R (P < 0.001). Furthermore, 35.0 % of patients with dominant 70Q/H exhibited SVR versus 77.4 % with dominant 70R (P < 0.001). However, regardless of the dominant strain, virological response types or the IL28B SNP genotypes, 70Q/H strains always exhibited the same response to treatment as the 70R strains and the percentage of HCV harboring the 70Q/H substitution did not change significantly during treatment. Conclusions: Although the ratio of 70Q/H to 70R is related to the virological response, 70Q/H strains always exhibited the same response as the 70R strains during PEG-IFN alpha/RBV treatment. Substitution of R70Q/H alone is not enough to lead to resistance to therapy. Positive selection for 70Q/H induced by IFN alpha was not observed.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] HCV genotype 2a shows a better virological response to antiviral therapy than HCV genotype 1b
    Wang, Meng
    Li, Jiansheng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 919 - 919
  • [22] NS5AISDR-V3 Region Genetic Variability of Tunisian HCV-1b Strains: Correlation With the Response to the Combined Interferon/Ribavirin Therapy
    Bouzgarrou, N.
    Hassen, E.
    Mahfoudh, W.
    Gabbouj, S.
    Schvoerer, E.
    Ben Yahia, A.
    Ben Mami, N.
    Triki, H.
    Chouchane, L.
    JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (12) : 2021 - 2028
  • [23] Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b
    Wang, Meng
    Zhang, Yi
    Li, Zhiqin
    Zhang, Hongyu
    Zhang, Zhen
    Yue, Dongli
    Zhou, Rong
    Li, Xiaogang
    Wu, Shuhuan
    Li, Jiansheng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (05): : 7446 - 7456
  • [24] Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy
    Derbala, M. F.
    El Dweik, N. Z.
    Al Kaabi, S. R.
    Al-Marri, A. D.
    Pasic, F.
    Bener, A. B.
    Shebl, F. M.
    Amer, A. M.
    Butt, M. T.
    Yakoob, R.
    John, A.
    Al Mohanadi, M.
    Al Khinji, M. A.
    JOURNAL OF VIRAL HEPATITIS, 2008, 15 (08) : 591 - 599
  • [25] Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads
    Sezaki, Hitomi
    Suzuki, Fumitaka
    Kawamura, Yusuke
    Yatsuji, Hiromi
    Hosaka, Tetsuya
    Akuta, Norio
    Kobayashi, Masahiro
    Suzuki, Yoshiyuki
    Saitoh, Satoshi
    Arase, Yasuji
    Ikeda, Kenji
    Miyakawa, Yuzo
    Kumada, Hiromitsu
    DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (06) : 1317 - 1324
  • [26] Relation of pretreatment sequence diversity in NS5A region of HCV genotype 1 with immune response between pegylated-INF/ribavirin therapy outcomes
    de Queiroz, A. T. L.
    Maracaja-Coutinho, V.
    Jardim, A. C. G.
    Rahal, P.
    de Carvalho-Mello, I. M. V. G.
    Matioli, S. R.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (02) : 142 - 148
  • [27] Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin
    Hayashi, Kazuhiko
    Katano, Yoshiaki
    Kuzuya, Teiji
    Tachi, Yoshihiko
    Honda, Takashi
    Ishigami, Masatoshi
    Itoh, Akihiro
    Hirooka, Yoshiki
    Ishikawa, Tetsuya
    Nakano, Isao
    Urano, Fumihiro
    Yoshioka, Kentaro
    Toyoda, Hidenori
    Kumada, Takashi
    Goto, Hidemi
    JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (03) : 438 - 444
  • [28] RESPONSE FACTORS TO PEGYLATED INTERFERON-ALFA/RIBAVIRIN TREATMENT IN CHRONIC HEPATITIS C PATIENTS GENOTYPE 1B
    Jovanovic-Cupic, Snezana
    Glisic, S.
    Stanojevic, M.
    Vasiljevic, N.
    Bojic-Milinovic, T.
    Bozovic, A.
    Dimitrijevic, B.
    ARCHIVES OF BIOLOGICAL SCIENCES, 2014, 66 (01) : 193 - 201
  • [29] Association of Interleukin-28B and Hepatitis C Genotype 1 with a High Viral Load and Response to Pegylated Interferon plus Ribavirin Therapy
    Takita, Masahiro
    Hagiwara, Satoru
    Arizumi, Tadaaki
    Hayaishi, Sousuke
    Ueda, Taisuke
    Kitai, Satoshi
    Yada, Norihisa
    Inoue, Tatsuo
    Minami, Yasunori
    Chung, Hobyung
    Ueshima, Kazuomi
    Sakurai, Toshiharu
    Kudo, Masatoshi
    DIGESTION, 2011, 84 : 56 - 61
  • [30] Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients
    Tsubota, Akihito
    Shimada, Noritomo
    Yoshizawa, Kai
    Furihata, Tomomi
    Agata, Rie
    Yumoto, Yoko
    Abe, Hiroshi
    Ika, Makiko
    Namiki, Yoshihisa
    Chiba, Kan
    Fujise, Kiyotaka
    Tada, Norio
    Aizawa, Yoshio
    LIVER INTERNATIONAL, 2012, 32 (05) : 826 - 836